Research & development
overview
We invest in innovative research and development.
Servier is committed to investing in innovative research and development through our own internal pipeline or partnerships to best address the unmet needs of patients.
Our innovations
At Servier Pharmaceuticals, we are committed to making the world a better place for the patients we serve. Our innovative research focuses on two key therapeutic areas: Oncology and Neurology. Our extensive know-how and expertise position us to best address the unmet needs of patients. Servier draws on the excellence of its Research & Development (R&D) employees worldwide to develop effective treatment solutions.
Our Therapeutic Areas
Servier Pharmaceuticals is committed to reinvesting in research to help discover new treatments that improve our patients’ lives. To fuel the next generation of discovery, we are reinvesting more of our total revenue back into our own R&D and innovative partnerships than into life-cycle management. We are not interested in investing in incremental projects but are looking to invest in the big advances that truly move the needle for our patients.
According to the World Health Organization, cancer is the second leading cause of death worldwide, with one out of every six deaths stemming from cancer-related diseases. Cancer was also responsible for approximately 9.6 million deaths in 2018. We are targeting our oncology research on immuno-oncology, cellular metabolism, and apoptosis. Prioritized indications are hematological malignancies and solid tumors, such as gastrointestinal (colon, gastric and pancreas), breast and lung cancers, as well as cholangiocarcinoma and glioma.
Based on data from the World Health Organization, more than one billion people are affected by neurological disease worldwide. At Servier, we are committed to addressing this major medical need in neurology, with a particular focus on refractory epilepsies, rare movement disorders and neuromuscular disorders. Our scientific focus targets a limited number of common mechanisms of action across these pathologies, enabling us to develop meaningful strategies to combat their progression. Our approach is based on patient-derived data and a high degree of biological evidence, including immunological data, providing a robust scientific basis for addressing these disorders.
Therapies in development are being investigated for patient use and are not approved by the FDA.